92 Chapter 4 REFERENCES 1. Ellul MA, Benjamin L, Singh B et al. Neurological associations of COVID-19. Lancet Neurol 2020; 19 (9): 767-783. 2. Van Casteren DS, Verhagen IE, De Boer I et al. E-diary use in clinical headache practice: A prospective observational study. Cephalalgia 2021; 41 (11-12): 1161-1171. 3. van der Arend BWH, Verhagen IE, van Leeuwen M et al. Defining migraine days, based on longitudinal E-diary data. Cephalalgia 2023; 43 (5). 4. Verhagen IE, Van Casteren DS, De Vries Lentsch S et al. Effect of lockdown during COVID-19 on migraine: A longitudinal cohort study. Cephalalgia 2021; 41 (7): 865-870. 5. De Vries Lentsch S, Verhagen IE, Van Den Hoek TC et al. Treatment with the monoclonal calcitonin gene-related peptide receptor antibody erenumab: A real-life study. European Journal of Neurology 2021; 28 (12): 4194-4203. 6. Gonzalez-Martinez A, Fanjul V, Ramos C et al. Headache during SARS-CoV-2 infection as an early symptom associated with a more benign course of disease: a case–control study. European Journal of Neurology 2021; 28 (10): 3426-3436. 7. Membrilla JA, de Lorenzo Í, Sastre M et al. Headache as a Cardinal Symptom of Coronavirus Disease 2019: A Cross-Sectional Study. Headache: The Journal of Head and Face Pain 2020; 60 (10): 2176-2191. 8. Al-Hashel JY, Ismail, II. Impact of coronavirus disease 2019 (COVID-19) pandemic on patients with migraine: a web-based survey study. J Headache Pain 2020; 21 (1): 115. 9. Sadoff J, Gray G, Vandebosch A et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med 2021; 384 (23): 2187-2201. 10. Voysey M, Clemens SAC, Madhi SA et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021; 397 (10269): 99-111. 11. Tiyo BT, Schmitz GJH, Ortega MM et al. What Happens to the Immune System after Vaccination or Recovery from COVID-19? Life (Basel) 2021; 11 (11). 12. Ewer KJ, Barrett JR, Belij-Rammerstorfer S et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med 2021; 27 (2): 270-278. 13. Polack FP, Thomas SJ, Kitchin N et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine 2020; 383 (27): 2603-2615. 14. Baden LR, El Sahly HM, Essink B et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021; 384 (5): 403-416. 15. Kamińska D, Dęborska-Materkowska D, Kościelska-Kasprzak K et al. Immunity after COVID-19 Recovery and Vaccination: Similarities and Differences. Vaccines (Basel) 2022; 10 (7). 16. Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nature Reviews Immunology 2021; 21 (2): 83-100.
RkJQdWJsaXNoZXIy MjY0ODMw